EUVIMEDEUVIMED entdecken
CrossrefInfokarte

GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis

Krishna Vamsy Polepalli, Prarath Roshni, Sushma Moka, Rinita Reddi, Mahesh Manish, Vineeth Potluri

Digestive Diseases · 2026-11-09

DOI: 10.1159/ddi/acnag020 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with high unmet therapeutic need. GLP-1/glucagon dual receptor agonists are an emerging drug class, but no meta-analysis has evaluated it exclusively. Methods: In this registered systematic review and meta-analysis (PROSPERO CRD420261325731), we searched PubMed, Embase, Cochrane, and Google Scholar through January 2026 for placebo-controlled randomized trials of GLP-1/glucagon dual agonists in adults with MASH or MASLD. Four trials (survodutide, pemvidutide, cotadutide; n=673) were pooled with DerSimonian-Laird random-effects models; Hartung-Knapp-Sidik-Jonkman adjustment was a sensitivity analysis. Results: Dual agonists increased MASH resolution without worsening of fibrosis (RR 2.98, 95% CI 2.09–4.24; k=2). A borderline, exploratory signal for fibrosis improvement was observed (RR 1.38, 95% CI 1.01–1.88; p=0.044; k=2); neither trial was individually significant. Relative liver fat fell by 46.24% (95% CI −55.24 to −37.24), and ≥30% liver fat reduction was more frequent (RR 4.39, 95% CI 2.97–6.49). ALT (MD −20.38 IU/L, 95% CI −33.00 to −7.75), AST (MD −18.80 IU/L), body weight (MD −4.36%) and systolic blood pressure (MD −5.22 mmHg) decreased; the ELF reduction was not retained in sensitivity analyses. Nausea (RR 2.90), vomiting (RR 9.58) and diarrhea (RR 1.90) were more frequent; serious adverse events were not (RR 1.06). Split-placebo analyses were consistent. Conclusions: Dual agonists were associated with a higher likelihood of MASH resolution, a borderline exploratory fibrosis signal, and reductions in liver fat, liver enzymes, weight and systolic blood pressure, with more gastrointestinal adverse events. These early-phase findings support continued Phase 3 evaluation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →